Cipla Ltd.

Cipla has received the Establishment Inspection Report (EIR) for the inspection done by United States Food and Drug Administration (USFDA) at the Kurkumbh manufacturing facility. The inspection was conducted from March 11, 2019 to March 20, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.